Nancy Baum Lipsitz remembers the night the pain began. She’d had a glass of white wine with a friend and went to bed with a terrible headache. The next day, she still felt horrible, the beginning of what she called a “rolling tide” of near constant migraines and lower level headaches.
(2018-12-01)
Read The Article in Health & Science, WhasingtonPost.com >>>
Ajovy is first anti-CGRP treatment available at monthly and quarterly doses
| The third new generation of CGRP antibody has been approved. It’s called Emgality (galcanezumab) which was just approved by the FDA on September 27th. |
| · Watch this interview preview with Professor Lars Edvinsson, the inventor of the CGRP monoclonal antibodies. |
| · Watch this interview preview with Professor Lars Edvinsson, the inventor of the CGRP monoclonal antibodies. |
(2018-09-14)
Read the article in MigraineAgain.com >>>
Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab (Emgality) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month.
Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function
(2018-11-20)
Läs artikeln på EMHAnews.com >>>
